-
"Logic gate" AAV gene therapy, let cancer cells "nowhere to escape" Medical Maihei Technology
Time of Update: 2022-01-09
Recently, a team of scientists from the Swiss Federal Institute of Technology Zurich has developed a logic-gated AAV gene therapy, which is used in combination with Roche's antiviral drug Cytovene (ganciclovir) in a mouse model of hepatocellular carcinoma It shows the potential of precisely targeting cancer cells, and can kill cancer cells more effectively while preserving healthy tissues, significantly reducing the tumor burden of hepatocellular carcinoma mice .
-
【News】Lolatinib for the treatment of ROS1-positive advanced NSCLC clinical trial approved in China
Time of Update: 2022-01-09
CStone Pharmaceuticals announced on January 4 that the clinical trial application (IND) of loratinib for ROS1-positive advanced non-small cell lung cancer (NSCLC) has been approved by the National Medical Products Administration (NMPA) of China .
-
Experts comment on Cancer Cell Fan Jia/Zhou Hu/Gao Daming/Gao Qiang to draw the multi-omics molecular feature panorama of intrahepatic cholangiocarcinoma
Time of Update: 2022-01-09
On December 30, 2021, Fan Jia, Academician of Zhongshan Hospital Affiliated to Fudan University, Researcher Zhou Hu from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Researcher Gao Daming from the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, and Professor Gao Qiang's research group from Zhongshan Hospital Affiliated to Fudan University collaborated in Cancer A research paper titled Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma was published on Cell.
-
When the greasy "Meta" meets the pure "Shengxin", what kind of sparks will it spark?
Time of Update: 2022-01-09
Prognostic analysis showed that the RFS of colon cancer patients in the chemotherapy group could be significantly differentiated in these cohorts by CRLSig (Figure 3A-3C) .
In addition to OS and RFS, CRLSig is also significantly related to the TNM staging of colon cancer patients undergoing chemotherapy (Figure 6B) .
-
Express develops tumor microenvironment to activate innovative immunotherapy, cutting-edge exploration of new strategies for solid tumor treatment
Time of Update: 2022-01-09
"Reference: [1] Amberstone Biosciences Secures $12 Million Series A Financing to Advance Immuno-Oncology Pipeline of Tumor Microenvironment Activated Therapeutics.
Retrieved January 3, 2021, from https:// en/Amberstone-Biosciences-Secures-12-Million-Series-A-Financing-to-Advance-Immuno-Oncology-Pipeline-of-Tumor-Microenvironment-Activated-Therapeutics Disclaimer: WuXi AppTec's content team focuses on introducing global biomedicine Health research progress .
-
Foreword Insights from Professor Ling Zhiqiang: Can these markers guide gastric cancer diagnosis and treatment?
Time of Update: 2022-01-09
lncRNA MT1JP inhibits gastric cancer cell proliferation, migration, invasion, and promotes apoptosis, which can be used as a potential therapeutic target and prognostic marker for gastric cancer .
-
Nature Summary: Highlights and Setbacks of Oncology Drugs in 2021
Time of Update: 2022-01-09
It was approved by the FDA based on a single-arm, open-label, phase i/ii trial that included patients with locally advanced or metastatic NSCLC with KRASG12C mutations .
-
Bleeding and thrombosis associated with CAR-T therapy
Time of Update: 2022-01-09
Comment This article introduces a relatively unknown toxicity of CAR-T therapy and identifies patients who need close follow-up, especially those with baseline thrombocytopenia or higher grade ICANS .
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy.
-
"Blood test for cancer" female version of Jobs convicted, is liquid biopsy reliable? NEJM review
Time of Update: 2022-01-09
In addition, compared with needle aspiration biopsy of a single tumor lesion, cfDNA analysis can better detect the molecular heterogeneity of multiple different clonal populations in a patient's tumor .
-
Courier CStone's potential "best-in-class" ROR1 antibody conjugate drug is approved by the US FDA to enter the clinic
Time of Update: 2022-01-09
▎This article is transferred from the official WeChat account of CStone Pharmaceuticals (Suzhou, China, January 3, 2022) CStone Pharmaceuticals (Hong Kong Stock Exchange code: 2616), a company that focuses on research, development and commercialization of innovative tumor immunotherapy and precision treatment drugs The leading biopharmaceutical company today announced that its CS5001 clinical trial application (IND) has been approved by the U.
-
How to adjust the treatment of breast cancer patients as the epidemic becomes normal?
Time of Update: 2022-01-09
*Only for medical professionals to read and reference Member of Shaanxi Provincial Health Promotion and Education Association, Examiner of Vocational Skills Appraisal Center Member of Immunotherapy C
-
[Nature Sub-Journal] A "high-risk, high-return" study-scientists transform CAR-T cells into cancer drugs "micro weapons"
Time of Update: 2022-01-09
To overcome these problems, a new type of CAR-T cell was developed, which is designed to express enzymes that activate systemically administered small molecule prodrugs in situ at the tumor site .
-
European Radiology: The value of MRI in differentiating benign and malignant pancreatic mucinous cystic tumors
Time of Update: 2022-01-08
Recently, published in the E uropean a journal Radiology study to assess the value of MRI in differentiating benign and malignant mucinous cystic pancreatic tumors , provides a valuable reference for the development of treatment programs preoperative assessment clinic .
-
Ther Adv Med Oncol: A retrospective study by Professor Zhong Zhong Shiming’s team found that lenvatinib + teriprizumab + hepatic arterial infusion chemotherapy (HAIC) can improve the prognosis of patients with advanced hepatocellular carcinoma
Time of Update: 2022-01-08
Studies have shown that compared with lenvatinib alone, the LeToHAIC group (Lenvatinib + toripalimab +HAIC) can improve the prognosis of patients with advanced hepatocellular carcinoma, and the toxicity is tolerable .
-
Eur Urol: Evaluation of the efficacy and safety of stereotactic radiotherapy and short-term pembrolizumab in the treatment of oligometastatic renal cell carcinoma
Time of Update: 2022-01-08
Stereotactic ablation radiotherapy (SABR) is the treatment of oligometastasis An option for clear cell renal cell carcinoma (ccRCC), but limited due to lack of prospective clinical trial dataRecently, researchers from Australia published an article in the journal Eur Urol.
-
Science Sub-Journal: Penn and Yale University jointly develop a new field of mRNA vaccines
Time of Update: 2022-01-08
Drew Weissman of the University of Pennsylvania has developed an mRNA-based vaccine designed to prevent Lyme disease by targeting the salivary protein of ticks .
The research results were published in Science Translational Medicine under the title "mRNA vaccination induces tick resistance and prevents transmission of the Lyme disease agent" .
-
The Lancet Magazine's new year's heavyweight: 300,000 15-year data revealed!
Time of Update: 2022-01-08
Throughout the study, the hospitalization rates for blood vessels, non-diabetic-related cancers, and amputations were higher in men than in women (Table 2) .
Throughout the study, the hospitalization rates for blood vessels, non-diabetic-related cancers, and amputations were higher in men than in women (Table 2) .
-
Radiology: Radiology model, so that clinical stage I lung adenocarcinoma has nowhere to hide!
Time of Update: 2022-01-08
Lung cancer is one of the most common cancers and the leading cause of cancer deaths worldwide . Among them , adenocarcinoma is the most common histological subtype . Surgical resection provides the
-
EBCAM: Curative Effect Observation of Modified Zishen Tongguan Decoction Combined with Acupuncture on Urinary Retention after Cervical Cancer Operation
Time of Update: 2022-01-08
statisticsConclusion: Modified Zishen Tongguan Decoction combined with acupuncture can significantly improve the therapeutic effect, bladder compliance and urine function of patients with urinary retention after cervical cancer surgery .
-
Selection of gastric cancer organoid models
Time of Update: 2022-01-08
Cell lines, animal models, and patient-derived tumor xenograft models all lack the characteristics that characterize the occurrence and development of gastric cancer, which limits the research on the pathogenesis of gastric cancer and the development of therapeutic drugs.